Compare Novo Nordisk A/S (NVO) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs PayPal Holdings, Inc. — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while PayPal Holdings, Inc. trades at $55.86 (market cap $50.12B). The key difference: Novo Nordisk A/S is far larger — about 4.4× PayPal Holdings, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | PYPL | |
|---|---|---|
Market Cap | $220.53B | $50.12B |
Sector | Health | Financials |
52-Week High | $71.70 | $78.22 |
52-Week Low | $35.29 | $39.08 |
Enterprise Value | $239.49B | $50.19B |
Dividend Yield | 3.63% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
PayPal (PYPL) trades at $55.85, down 1.26% today, amid takeover speculation from Stripe and Advent International. The stock shows strong fundamentals with a P/E of 10.66 and net income margin of 15%, while technical indicators are mixed with a bullish moving average signal but overbought RSI levels. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow from operations of $6.42 billion in 2025.
The outlook is clouded by the potential buyout, which could limit upside if the offer is rejected, while profitability pressures and competition from Apple Pay pose risks. Analyst consensus is cautious with a hold-heavy rating, suggesting investors await clarity on strategic direction amid the takeover bid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
